Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 10, 2025Discover OncologyOpen Access

A meta-analysis based on propensity analysis studies comparing neoadjuvant immunochemotherapy and neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

ZJZixian JinJZJiani ZhuJZJian Zhang

Discussion

Loading...

Member takes

Overview

Meta-analysis reveals neoadjuvant immunochemotherapy improves overall survival in ESCC patients, suggesting a shift in treatment approach.

Key Points

  • Neoadjuvant immunochemotherapy demonstrated significant overall survival improvements compared to chemoradiotherapy in esophageal squamous cell carcinoma.
  • The analysis of 11 studies with 4,684 patients showed a hazard ratio of 0.61 for overall survival favoring immunochemotherapy.
  • A propensity score analysis compared the two neoadjuvant approaches, focusing on primary outcomes like disease-free survival and pathological response rates.
  • While immunochemotherapy provided better survival rates, the rates for pathological complete response and major pathological response were lower than chemoradiotherapy.

Cite This Study

Jin et al. (2025) studied this question.

synapsesocial.com/papers/68e9435d2d5336d28fb28974https://doi.org/10.1007/s12672-025-03607-8
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a clinical retrospective study2025
  2. 2Comparative efficacy and safety of neoadjuvant immunochemotherapy versus chemotherapy in locally advanced esophageal squamous cell carcinoma: a dual-center retrospective study2025
  3. 3Efficacy of neoadjuvant chemoimmunotherapy in locally advanced resectable esophageal cancer2025
  4. 4Neoadjuvant chemoimmunotherapy versus neoadjuvant chemoradiotherapy in patients with borderline resectable esophageal squamous cell carcinoma2025
  5. 5Comparative study of neoadjuvant chemoradiotherapy, chemotherapy, and chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma2025 · 1 citations